<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7570423\results\search\disease\results.xml">
  <result pre="doi: 10.1038/s41581-020-00357-4 : Review Article Immunity, endothelial injury and complement-induced" exact="coagulopathy" post="in COVID-19 http://orcid.org/0000-0003-3470-1721PericoLuca1BenigniAriela1CasiraghiFederica1http://orcid.org/0000-0003-4071-5222NgLisa F. P.234http://orcid.org/0000-0003-0349-1557ReniaLaurent23http://orcid.org/0000-0002-6194-3446RemuzziGiuseppegiuseppe.remuzzi@marionegri.it15[1], grid.4527.40000000106678902Istituto di Ricerche Farmacologiche"/>
  <result pre="Ricerche Farmacologiche Mario Negri IRCCS, [2], grid.185448.40000 0004 0637 0221Infectious" exact="Diseases" post="Horizontal Technology Centre (ID HTC), Agency for Science, Technology"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="In December 2019, a novel coronavirus was isolated from the" exact="respiratory" post="epithelium of patients with unexplained pneumonia in Wuhan, China."/>
  <result pre="was isolated from the respiratory epithelium of patients with unexplained" exact="pneumonia" post="in Wuhan, China. This pathogen, named severe acute respiratory"/>
  <result pre="with unexplained pneumonia in Wuhan, China. This pathogen, named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), causes a pathogenic condition"/>
  <result pre="unexplained pneumonia in Wuhan, China. This pathogen, named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), causes a pathogenic condition that"/>
  <result pre="pneumonia in Wuhan, China. This pathogen, named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), causes a pathogenic condition that has"/>
  <result pre="(SARS-CoV-2), causes a pathogenic condition that has been termed coronavirus" exact="disease" post="2019 (COVID-19) and has reached pandemic proportions. As of"/>
  <result pre="of 17 September 2020, more than 30 million confirmed SARS-CoV-2" exact="infections" post="have been reported in 204 different countries, claiming more"/>
  <result pre="than 1 million lives worldwide. Accumulating evidence suggests that SARS-CoV-2" exact="infection" post="can lead to a variety of clinical conditions, ranging"/>
  <result pre="20% of patients rapidly progress to severe illness characterized by" exact="atypical" post="interstitial bilateral pneumonia, acute respiratory distress syndrome and multiorgan"/>
  <result pre="patients rapidly progress to severe illness characterized by atypical interstitial" exact="bilateral" post="pneumonia, acute respiratory distress syndrome and multiorgan dysfunction. Almost"/>
  <result pre="progress to severe illness characterized by atypical interstitial bilateral pneumonia," exact="acute" post="respiratory distress syndrome and multiorgan dysfunction. Almost 10% of"/>
  <result pre="to severe illness characterized by atypical interstitial bilateral pneumonia, acute" exact="respiratory" post="distress syndrome and multiorgan dysfunction. Almost 10% of these"/>
  <result pre="illness characterized by atypical interstitial bilateral pneumonia, acute respiratory distress" exact="syndrome" post="and multiorgan dysfunction. Almost 10% of these critically ill"/>
  <result pre="patients subsequently die. Insights into the pathogenic mechanisms underlying SARS-CoV-2" exact="infection" post="and COVID-19 progression are emerging and highlight the critical"/>
  <result pre="â€&quot; characterized by widespread endothelial damage, complement-induced blood clotting and" exact="systemic" post="microangiopathy â€&quot; in disease exacerbation. These insights may aid"/>
  <result pre="endothelial damage, complement-induced blood clotting and systemic microangiopathy â€&quot; in" exact="disease" post="exacerbation. These insights may aid the identification of new"/>
  <result pre="or existing therapeutic interventions to limit the progression of early" exact="disease" post="and treat severe cases. This Review describes our current"/>
  <result pre="our current understanding of the pathogenic mechanisms involved in severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the progression"/>
  <result pre="current understanding of the pathogenic mechanisms involved in severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection and the progression of"/>
  <result pre="understanding of the pathogenic mechanisms involved in severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection and the progression of coronavirus"/>
  <result pre="mechanisms involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="and the progression of coronavirus disease 2019 (COVID-19), focusing"/>
  <result pre="syndrome coronavirus 2 (SARS-CoV-2) infection and the progression of coronavirus" exact="disease" post="2019 (COVID-19), focusing on the immunological hyper-response and the"/>
  <result pre="the induction of widespread endothelial damage, complement-associated blood clotting and" exact="systemic" post="microangiopathy, as well as the effects of these processes"/>
  <result pre="most promise. Key points Although most patients infected with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) experience mild to moderate"/>
  <result pre="promise. Key points Although most patients infected with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) experience mild to moderate symptoms"/>
  <result pre="Key points Although most patients infected with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) experience mild to moderate symptoms that"/>
  <result pre="days, almost 20% of patients develop severe illness characterized by" exact="atypical" post="interstitial bilateral pneumonia and acute respiratory distress syndrome, with"/>
  <result pre="20% of patients develop severe illness characterized by atypical interstitial" exact="bilateral" post="pneumonia and acute respiratory distress syndrome, with a high"/>
  <result pre="of patients develop severe illness characterized by atypical interstitial bilateral" exact="pneumonia" post="and acute respiratory distress syndrome, with a high fatality"/>
  <result pre="develop severe illness characterized by atypical interstitial bilateral pneumonia and" exact="acute" post="respiratory distress syndrome, with a high fatality rate. Accumulating"/>
  <result pre="severe illness characterized by atypical interstitial bilateral pneumonia and acute" exact="respiratory" post="distress syndrome, with a high fatality rate. Accumulating evidence"/>
  <result pre="expense of effective adaptive immunity, underpins the progression of coronavirus" exact="disease" post="2019 (COVID-19). In severe cases of COVID-19, massive endothelial"/>
  <result pre="(COVID-19). In severe cases of COVID-19, massive endothelial dysfunction, widespread" exact="coagulopathy" post="and complement-induced thrombosis can lead to the development of"/>
  <result pre="cases of COVID-19, massive endothelial dysfunction, widespread coagulopathy and complement-induced" exact="thrombosis" post="can lead to the development of systemic microangiopathy and"/>
  <result pre="coagulopathy and complement-induced thrombosis can lead to the development of" exact="systemic" post="microangiopathy and thromboembolism; these complications can be life-threatening and"/>
  <result pre="the host response, including the hyper-immune response, complement activation and" exact="systemic" post="thrombosis, seem to be more promising approaches to the"/>
  <result pre="promising approaches to the treatment of severe COVID-19. Subject terms" exact="Kidney" post="diseases Infectious diseases SARS-CoV-2 Kidney Introduction Coronaviruses are enveloped,"/>
  <result pre="to the treatment of severe COVID-19. Subject terms Kidney diseases" exact="Infectious" post="diseases SARS-CoV-2 Kidney Introduction Coronaviruses are enveloped, single-stranded RNA"/>
  <result pre="of severe COVID-19. Subject terms Kidney diseases Infectious diseases SARS-CoV-2" exact="Kidney" post="Introduction Coronaviruses are enveloped, single-stranded RNA viruses (Fig.Â 1a)."/>
  <result pre="several coronaviruses that can infect mammals and birds. Although such" exact="infections" post="usually cause mild respiratory disease, in the past two"/>
  <result pre="infect mammals and birds. Although such infections usually cause mild" exact="respiratory" post="disease, in the past two decades, coronaviruses have caused"/>
  <result pre="decades, coronaviruses have caused two epidemic diseases in humans: severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)"/>
  <result pre="coronaviruses have caused two epidemic diseases in humans: severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS) in"/>
  <result pre="have caused two epidemic diseases in humans: severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS) in 2003"/>
  <result pre="in humans: severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS) in 2003 and 2012, respectively. Severe acute"/>
  <result pre="humans: severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS) in 2003 and 2012, respectively. Severe acute respiratory"/>
  <result pre="Middle East respiratory syndrome (MERS) in 2003 and 2012, respectively." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel"/>
  <result pre="East respiratory syndrome (MERS) in 2003 and 2012, respectively. Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus"/>
  <result pre="respiratory syndrome (MERS) in 2003 and 2012, respectively. Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that"/>
  <result pre="syndrome (MERS) in 2003 and 2012, respectively. Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is a novel coronavirus that was"/>
  <result pre="(SARS-CoV-2) is a novel coronavirus that was isolated from the" exact="respiratory" post="epithelium of patients with unexplained pneumonia in Wuhan, China,"/>
  <result pre="was isolated from the respiratory epithelium of patients with unexplained" exact="pneumonia" post="in Wuhan, China, in December 2019. As of 17"/>
  <result pre="China, in December 2019. As of 17 September 2020, the" exact="disease" post="caused by SARS-CoV-2, named coronavirus disease 2019 (COVID-19), has"/>
  <result pre="17 September 2020, the disease caused by SARS-CoV-2, named coronavirus" exact="disease" post="2019 (COVID-19), has reached pandemic proportions, affecting more than"/>
  <result pre="1 SARS-CoV-2 structure, genome composition and life cycle. a |" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a typical"/>
  <result pre="SARS-CoV-2 structure, genome composition and life cycle. a | Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is a typical betacoronavirus"/>
  <result pre="structure, genome composition and life cycle. a | Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is a typical betacoronavirus belonging"/>
  <result pre="genome composition and life cycle. a | Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is a typical betacoronavirus belonging the"/>
  <result pre="envelope (E) protein and the membrane (M) protein. Within the" exact="viral" post="envelope, the nucleocapsid (N) protein holds the positive-sense single-stranded"/>
  <result pre="ten open reading frames (ORFs). At least two-thirds of the" exact="viral" post="genome are contained in ORF1a and ORF1b, which together"/>
  <result pre="and primes S glycoprotein, leading to the fusion of the" exact="viral" post="and cell membranes. In addition to canonical viral entry"/>
  <result pre="of the viral and cell membranes. In addition to canonical" exact="viral" post="entry via the endosomal pathway, non-endosomal entry at the"/>
  <result pre="non-endosomal entry at the plasma membrane may be an additional" exact="infection" post="route for SARS-CoV-2. Within the target cells, SARS-CoV-2 is"/>
  <result pre="the target cells, SARS-CoV-2 is disassembled to release nucleocapsid and" exact="viral" post="RNA into the cytoplasm for translation and replication. Translated"/>
  <result pre="viral RNA into the cytoplasm for translation and replication. Translated" exact="viral" post="proteins are then assembled in the endoplasmic reticulum (ER)"/>
  <result pre="likely natural SARS-CoV-2 reservoir1, although phylogenetic studies have suggested that" exact="intermediate" post="animal hosts may have mediated zoonotic transmission to humans2â€&quot;5."/>
  <result pre="SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) complex, which is essential for" exact="viral" post="replication7. The near-atomic resolution of the NSP12â€&quot;NSP7â€&quot;NSP8 complex revealed"/>
  <result pre="polymerase activity and thermostability of the SARS-CoV-2 RdRp complex was" exact="lower" post="than that of the SARS-CoV RdRp complex, suggesting adaptation"/>
  <result pre="RdRp complex, suggesting adaptation of SARS-CoV-2 towards humans, which have" exact="lower" post="body temperatures than bats7. The other ORFs encode the"/>
  <result pre="as well as several accessory proteins with unknown functions1,6. SARS-CoV-2" exact="infection" post="(Fig.Â 1c) begins when the viral spike protein attaches"/>
  <result pre="with unknown functions1,6. SARS-CoV-2 infection (Fig.Â 1c) begins when the" exact="viral" post="spike protein attaches to its complementary host cell receptor9."/>
  <result pre="primes the receptor-bound spike protein to mediate fusion of the" exact="viral" post="envelope with the membrane of the target cell in"/>
  <result pre="host cell through endocytosis or via direct fusion of the" exact="viral" post="envelope with the host cell membrane. Once inside its"/>
  <result pre="the host cell membrane. Once inside its target cell, the" exact="viral" post="particles are uncoated and the released viral genome is"/>
  <result pre="target cell, the viral particles are uncoated and the released" exact="viral" post="genome is translated by the host ribosome in the"/>
  <result pre="translated by the host ribosome in the endoplasmic reticulum9. The" exact="viral" post="structural proteins move along the secretory pathway into the"/>
  <result pre="structural proteins move along the secretory pathway into the Golgi" exact="intermediate" post="compartment for progeny assembly, and the progeny are then"/>
  <result pre="the current understanding of the pathogenic mechanisms involved in SARS-CoV-2" exact="infection" post="and progression of COVID-19, focusing on the critical role"/>
  <result pre="focusing on the critical role of the immunological hyper-response in" exact="disease" post="exacerbation. We also examine emerging data in support of"/>
  <result pre="examine emerging data in support of a role for SARS-CoV-2" exact="infection" post="in inducing widespread endothelial damage, complement-associated blood clotting and"/>
  <result pre="infection in inducing widespread endothelial damage, complement-associated blood clotting and" exact="systemic" post="microangiopathy, and describe how these consequences may contribute to"/>
  <result pre="interventions that currently hold most promise to limit progression of" exact="disease" post="during the early phases and discuss currently available drugs"/>
  <result pre="may be repurposed to treat severe cases of COVID-19. SARS-CoV-2" exact="infection" post="and COVID-19 The human-to-human transmission of SARS-CoV-2 is primarily"/>
  <result pre="COVID-19 The human-to-human transmission of SARS-CoV-2 is primarily mediated by" exact="respiratory" post="droplets or aerosols generated during coughing and sneezing. In"/>
  <result pre="For about 80% of infected patients, COVID-19 is a mild" exact="disease" post="that is mostly restricted to the upper and conducting"/>
  <result pre="is a mild disease that is mostly restricted to the" exact="upper" post="and conducting airways. These individuals normally exhibit modest symptoms,"/>
  <result pre="spontaneously within 6â€&quot;10 days. However, in almost 20% of patients" exact="viral infection" post="progresses down the trachea to the lungs21. Within the"/>
  <result pre="within 6â€&quot;10 days. However, in almost 20% of patients viral" exact="infection" post="progresses down the trachea to the lungs21. Within the"/>
  <result pre="down the trachea to the lungs21. Within the alveoli, the" exact="epithelial" post="cells lining the lower airways are the main viral"/>
  <result pre="the lungs21. Within the alveoli, the epithelial cells lining the" exact="lower" post="airways are the main viral targets17,18, owing to their"/>
  <result pre="the epithelial cells lining the lower airways are the main" exact="viral" post="targets17,18, owing to their substantial expression of ACE2 and"/>
  <result pre="owing to their substantial expression of ACE2 and TMPRSS2. SARS-CoV-2" exact="infection" post="induces these epithelial cells to undergo apoptotic cell death"/>
  <result pre="substantial expression of ACE2 and TMPRSS2. SARS-CoV-2 infection induces these" exact="epithelial" post="cells to undergo apoptotic cell death as part of"/>
  <result pre="cells to undergo apoptotic cell death as part of the" exact="viral" post="replication cycle. This apoptotic response is associated with vascular"/>
  <result pre="the viral replication cycle. This apoptotic response is associated with" exact="vascular" post="leakage within alveoli that induces a first wave of"/>
  <result pre="propagating the local inflammatory response that underlies the pathology of" exact="atypical" post="interstitial bilateral pneumonia observed in patients with COVID-19. Histology"/>
  <result pre="local inflammatory response that underlies the pathology of atypical interstitial" exact="bilateral" post="pneumonia observed in patients with COVID-19. Histology studies have"/>
  <result pre="inflammatory response that underlies the pathology of atypical interstitial bilateral" exact="pneumonia" post="observed in patients with COVID-19. Histology studies have revealed"/>
  <result pre="lung is the most affected region, with pneumocyte injury and" exact="diffuse" post="alveolar damage, oedema and alveolar haemorrhage, and the presence"/>
  <result pre="inflammatory infiltrates24â€&quot;26. During this inflammatory phase in the lungs, the" exact="disease" post="can rapidly progress to severe illness characterized by acute"/>
  <result pre="the disease can rapidly progress to severe illness characterized by" exact="acute" post="respiratory distress syndrome (ARDS), a hyperinflammatory state and multiorgan"/>
  <result pre="disease can rapidly progress to severe illness characterized by acute" exact="respiratory" post="distress syndrome (ARDS), a hyperinflammatory state and multiorgan dysfunction"/>
  <result pre="rapidly progress to severe illness characterized by acute respiratory distress" exact="syndrome" post="(ARDS), a hyperinflammatory state and multiorgan dysfunction with a"/>
  <result pre="reduce multiorgan failure and mortality29,30. Although the lung is the" exact="primary" post="site of pathology, an accumulating body of evidence shows"/>
  <result pre="can be affected by SARS-CoV-2 infection, potentially leading to specific" exact="disease" post="manifestations such as anosmia and ageusia31,32, ocular conjunctivitis33, abdominal"/>
  <result pre="leading to specific disease manifestations such as anosmia and ageusia31,32," exact="ocular" post="conjunctivitis33, abdominal pain and diarrhoea34,35, or cardiac injury36. Many"/>
  <result pre="in vivo studies37â€&quot;39. Greater insight into the molecular mechanisms underlying" exact="disease" post="progression may aid the identification of therapeutic approaches to"/>
  <result pre="suggests that a suboptimal or unrestrained immune response during SARS-CoV-2" exact="infection" post="drives the clinical patterns, disease severity and progression of"/>
  <result pre="unrestrained immune response during SARS-CoV-2 infection drives the clinical patterns," exact="disease" post="severity and progression of COVID-19. Identification of specific immune"/>
  <result pre="specific immune signatures may provide novel insights into the divergent" exact="disease" post="trajectories observed in individual patients and aid the design"/>
  <result pre="innate immune system is the first line of defence against" exact="viral" post="infections43. When viruses colonize their target cells, viral single-stranded"/>
  <result pre="defence against viral infections43. When viruses colonize their target cells," exact="viral" post="single-stranded RNA, like that of SARS-CoV-2, activates innate immune"/>
  <result pre="Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I)-like receptors and" exact="melanoma" post="differentiation-associated gene 5 (MDA5), which sense aberrant RNA structures"/>
  <result pre="(MDA5), which sense aberrant RNA structures that often form during" exact="viral" post="replication44. Following PRR activation, molecular signalling cascades culminate in"/>
  <result pre="initial cellular antiviral defences by inducing the transcriptional activation of" exact="type I" post="and III interferons (IFN-I and IFN-III) and interferon-stimulated genes"/>
  <result pre="Fig. 2 Pathogenesis and outcomes of COVID-19. a | Following" exact="infection" post="of the lungs, (severe acute respiratory syndrome coronavirus 2"/>
  <result pre="of COVID-19. a | Following infection of the lungs, (severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) induces the death of"/>
  <result pre="COVID-19. a | Following infection of the lungs, (severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) induces the death of epithelial"/>
  <result pre="a | Following infection of the lungs, (severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) induces the death of epithelial cells,"/>
  <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces the death of" exact="epithelial" post="cells, in particular, type II pneumocytes, as part of"/>
  <result pre="2 (SARS-CoV-2) induces the death of epithelial cells, in particular," exact="type II" post="pneumocytes, as part of the viral replication cycle. Macrophages"/>
  <result pre="cells, in particular, type II pneumocytes, as part of the" exact="viral" post="replication cycle. Macrophages and neutrophils elicit a specific innate"/>
  <result pre="granulocyte-colony-stimulating factor (GCSF), interferon-Î³ (IFNÎ³), IFNÎ³ inducible protein 10 (IP-10)," exact="monocyte" post="chemoattractant protein 1 and 3 (MCP1 and 3), macrophage"/>
  <result pre="also enhance effector CD8+ T cell and NK responses during" exact="viral" post="infections. This orchestrated immune response leads to viral eradication"/>
  <result pre="responses during viral infections. This orchestrated immune response leads to" exact="viral" post="eradication and resolution of the disease. In these patients,"/>
  <result pre="eradication and resolution of the disease. In these patients, coronavirus" exact="disease" post="2019 (COVID-19) seems to manifest as a mild disease"/>
  <result pre="coronavirus disease 2019 (COVID-19) seems to manifest as a mild" exact="disease" post="with symptoms similar to the common flu that resolve"/>
  <result pre="For unknown reasons, but possibly individual predisposition or differences in" exact="viral" post="loads during primary SARS-CoV-2 infection, some patients experience more"/>
  <result pre="but possibly individual predisposition or differences in viral loads during" exact="primary" post="SARS-CoV-2 infection, some patients experience more severe disease. A"/>
  <result pre="experience more severe disease. A maladaptive immune response, characterized by" exact="lymphopenia" post="and suppression of CD4+ T cells, is likely accountable"/>
  <result pre="accountable for the poor prognosis of these patients. In the" exact="absence of" post="robust CD4+ T cell activation, B cells generate a"/>
  <result pre="polyclonal antibody response that may be ineffective in neutralizing SARS-CoV-2." exact="Increased" post="numbers of exhausted T cells that express high levels"/>
  <result pre="2 member A (NKG2A). Impaired cytotoxic activity results in persistent" exact="viral" post="shedding that amplifies macrophage and neutrophil activation, leading to"/>
  <result pre="patients, COVID-19 manifests as a severe disease, consisting of advanced" exact="pneumonia" post="and acute respiratory distress syndrome. The generation of excess"/>
  <result pre="manifests as a severe disease, consisting of advanced pneumonia and" exact="acute" post="respiratory distress syndrome. The generation of excess cytokines and"/>
  <result pre="as a severe disease, consisting of advanced pneumonia and acute" exact="respiratory" post="distress syndrome. The generation of excess cytokines and persistent"/>
  <result pre="respiratory distress syndrome. The generation of excess cytokines and persistent" exact="viral infection" post="leads to systemic vascular damage, disseminated intravascular coagulation (DIC)"/>
  <result pre="distress syndrome. The generation of excess cytokines and persistent viral" exact="infection" post="leads to systemic vascular damage, disseminated intravascular coagulation (DIC)"/>
  <result pre="generation of excess cytokines and persistent viral infection leads to" exact="systemic" post="vascular damage, disseminated intravascular coagulation (DIC) and the failure"/>
  <result pre="of excess cytokines and persistent viral infection leads to systemic" exact="vascular" post="damage, disseminated intravascular coagulation (DIC) and the failure of"/>
  <result pre="cytokines and persistent viral infection leads to systemic vascular damage," exact="disseminated intravascular coagulation" post="(DIC) and the failure of vital organs, including the"/>
  <result pre="mitochondrial membrane is essential for the activation of IFN-I after" exact="infection" post="of RNA viruses49, and it is possible that SARS-CoV-2"/>
  <result pre="translocation and IFN-I activation50. In support of this hypothesis, SARS-CoV-2" exact="infection" post="is associated with lower IFN-I and IFN-III levels and"/>
  <result pre="In support of this hypothesis, SARS-CoV-2 infection is associated with" exact="lower" post="IFN-I and IFN-III levels and a moderate ISG response"/>
  <result pre="IFN-III levels and a moderate ISG response compared with other" exact="respiratory" post="viruses, despite being characterized by vigorous production of inflammatory"/>
  <result pre="(G-CSF), IFNÎ³ inducible protein 10 (IP-10, also known as CXCL10)," exact="monocyte" post="chemoattractant protein 1 and 3 (MCP1 and MCP3, also"/>
  <result pre="COVID-19 (ref.54). These findings are reminiscent of the hyper-inflammatory syndrome," exact="secondary" post="haemophagocytic lymphohistiocytosis, and consequently, the immune response to SARS-CoV-2"/>
  <result pre="secondary haemophagocytic lymphohistiocytosis, and consequently, the immune response to SARS-CoV-2" exact="infection" post="was initially considered to involve a form of cytokine"/>
  <result pre="cytokine storm, similar to that found in patients with other" exact="viral" post="infections or sepsis, as well as in patients with"/>
  <result pre="storm, similar to that found in patients with other viral" exact="infections" post="or sepsis, as well as in patients with autoimmune"/>
  <result pre="viral infections or sepsis, as well as in patients with" exact="autoimmune" post="conditions such as arthritis55,56. However, this concept has since"/>
  <result pre="that SARS-CoV-2 spike proteins interact with CD68+ macrophages, suggesting direct" exact="viral infection" post="of these cells59. Single-cell RNA sequencing of immune cells"/>
  <result pre="SARS-CoV-2 spike proteins interact with CD68+ macrophages, suggesting direct viral" exact="infection" post="of these cells59. Single-cell RNA sequencing of immune cells"/>
  <result pre="decrease in tissue-resident reparative alveolar macrophages in patients with severe" exact="disease" post="compared with that seen in moderate cases60. A further"/>
  <result pre="macrophages61. Moreover, use of untargeted metabolomics has shown that SARS-CoV-2" exact="infection" post="triggers profound alterations in macrophage phenotype and function by"/>
  <result pre="towards anti-inflammatory phenotype62,63. Mechanistically, virusâ€&quot;host interactome and proteomic analysis of" exact="peripheral" post="blood cells from patients with varying symptoms of COVID-19"/>
  <result pre="fluid cells from eight patients with COVID-19 suggested that SARS-CoV-2" exact="infection" post="elicits more pronounced neutrophil infiltration than other forms of"/>
  <result pre="may exacerbate the hyper-inflammatory response in severe cases of the" exact="disease" post="(Fig.Â 2b). Adaptive immune response Lymphopenia is a common"/>
  <result pre="with COVID-19 severity and associated mortality72,73. A proteomic analysis of" exact="peripheral" post="blood cells from patients with COVID-19 reported decreased T"/>
  <result pre="with reduced indices of T cell activation and function, including" exact="lower" post="expression of T cell receptor (TCR) subunits (CD3e, CD3g,"/>
  <result pre="(CD3e, CD3g, CD247, TRAC and TRBC1) in patients with severe" exact="disease" post="than in patients with mild disease64. Levels of T"/>
  <result pre="II molecules (HLA-DRA, HLA-DRB1, HLA-DRB4 and HLA-DRB5) were also significantly" exact="lower" post="in patients with severe disease, indicating a global impairment"/>
  <result pre="global impairment in the adaptive immune response64. Decreased numbers of" exact="peripheral" post="T cells might result from increased migration to the"/>
  <result pre="that the rise in inflammatory cytokine levels induced by SARS-CoV-2" exact="infection" post="might drive the depletion of T and NK cells,"/>
  <result pre="which subsequently fail to destroy infected cells. However, T cell" exact="lymphopenia" post="may also result from SARS-CoV-2-induced cell death. Findings from"/>
  <result pre="results from AICD. Regardless of the underlying cause, however, the" exact="absence of" post="an effective anti-viral T cell and NK cell response"/>
  <result pre="play a critical part in the maintenance of a high" exact="viral" post="load and hyperactivation of the innate response77 (Fig.Â 2b)."/>
  <result pre="viral load and hyperactivation of the innate response77 (Fig.Â 2b)." exact="Severe" post="infection caused by SARS-CoV-2 has been likened to lymphopenic"/>
  <result pre="load and hyperactivation of the innate response77 (Fig.Â 2b). Severe" exact="infection" post="caused by SARS-CoV-2 has been likened to lymphopenic community-acquired"/>
  <result pre="defects in the T cell response might contribute to sustained" exact="viral" post="shedding and pathogenesis of multi-organ dysfunction in patients with"/>
  <result pre="against SARS-CoV-2 was identified as a classical T helper (TH)" exact="type 1" post="response, which was robust against the spike protein, the"/>
  <result pre="at least eight different SARS-CoV-2 ORFs81,82. Ex vivo stimulation with" exact="viral" post="peptides induced SARS-CoV-2-specific CD4+ and CD8+ T cells; in"/>
  <result pre="they responded to were significantly higher in patients with severe" exact="disease" post="than in patients with mild disease82,84, raising the question"/>
  <result pre="immunity89â€&quot;91. Non-human primates reinfected with SARS-CoV-2 &amp;lt;1â€‰month after their first" exact="infection" post="displayed a reduced viral load and prevented disease recurrence"/>
  <result pre="with SARS-CoV-2 &amp;lt;1â€‰month after their first infection displayed a reduced" exact="viral" post="load and prevented disease recurrence relative to responses in"/>
  <result pre="their first infection displayed a reduced viral load and prevented" exact="disease" post="recurrence relative to responses in primo-infected animals92,93; these beneficial"/>
  <result pre="vaccination. However, the extent to which naturally induced antibodies against" exact="disease" post="relapse may provide long-lasting protection is still unknown. The"/>
  <result pre="the finding that 40% of asymptomatic patients and 13% of" exact="symptomatic" post="patients became negative for anti-spike IgG in the early"/>
  <result pre="in a preprint study, longitudinal evaluation of patients with SARS-CoV-2" exact="infection" post="reported a rapid decline in levels of neutralizing antibody"/>
  <result pre="antibody during a 4-month follow-up period, with titres approaching the" exact="lower" post="threshold of positivity in several individuals96. The decay of"/>
  <result pre="in the Icelandic population showing that antibodies against SARS-CoV-2 remained" exact="stable" post="for over 4 months98. More importantly, neutralizing antibodies from"/>
  <result pre="suggesting that they bind SARS-CoV-2 with low affinity owing to" exact="limited" post="affinity maturation99; indeed, these antibodies have modest neutralizing activity100,101,"/>
  <result pre="with severe COVID-19 compared with responses in patients with mild" exact="disease" post="or healthy individuals42,102,103. The antibody sequences of the largest"/>
  <result pre="Unfortunately, this study did not assess the potential correlation between" exact="viral" post="load and disease symptoms with neutralizing antibody titres in"/>
  <result pre="did not assess the potential correlation between viral load and" exact="disease" post="symptoms with neutralizing antibody titres in individual patients to"/>
  <result pre="adaptive immunity, including the cellular and humoral response to SARS-CoV-2" exact="infection" post="(Fig.Â 2). These findings indicate the need for further"/>
  <result pre="7 April, 2020, researchers observed a sevenfold increase in large-vessel" exact="stroke" post="among patients younger than 50 years of age compared"/>
  <result pre="Although early evidence suggested that children may be at a" exact="lower" post="risk of SARS-CoV-2 infection than adults owing to the"/>
  <result pre="that children may be at a lower risk of SARS-CoV-2" exact="infection" post="than adults owing to the lower expression of ACE2"/>
  <result pre="lower risk of SARS-CoV-2 infection than adults owing to the" exact="lower" post="expression of ACE2 in nasal epithelia117, an unprecedented cluster"/>
  <result pre="ACE2 in nasal epithelia117, an unprecedented cluster of hyper-inflammatory shock" exact="syndrome" post="was observed in South East England, UK over a"/>
  <result pre="2020 in eight children with likely family COVID-19 exposure118. This" exact="syndrome" post="has been described as a pathological condition with features"/>
  <result pre="been described as a pathological condition with features similar to" exact="Kawasaki disease" post="â€&quot; a rare condition that affects blood vessels, including"/>
  <result pre="described as a pathological condition with features similar to Kawasaki" exact="disease" post="â€&quot; a rare condition that affects blood vessels, including"/>
  <result pre="similar to Kawasaki disease â€&quot; a rare condition that affects" exact="blood vessels," post="including those in the heart. All children tested negative"/>
  <result pre="lavage or nasopharyngeal aspirates, but laboratory tests were indicative of" exact="infection" post="and inflammation, including high levels of C-reactive protein, ferritin"/>
  <result pre="recent evidence suggested that this syndrome, now termed multisystem inflammatory" exact="syndrome" post="in children (MIS-C), has unique haematological and immunological characteristics"/>
  <result pre="retrospective study of 35 children with MIS-C in France described" exact="acute" post="heart failure as a result of the severe inflammatory"/>
  <result pre="study of 35 children with MIS-C in France described acute" exact="heart" post="failure as a result of the severe inflammatory state"/>
  <result pre="caused by SARS-CoV-2 infection; none of these children had underlying" exact="cardiovascular" post="disease122. SARS-CoV-2 may alter vascular homeostasis by directly infecting"/>
  <result pre="of these children had underlying cardiovascular disease122. SARS-CoV-2 may alter" exact="vascular" post="homeostasis by directly infecting endothelial cells via ACE2 (Fig.Â"/>
  <result pre="of post-mortem tissue, which have shown that SARS-CoV-2 can infect" exact="pulmonary" post="endothelial cells and induce endotheliitis, at least in a"/>
  <result pre="of ACE2 expression by endothelial cells in response to SARS-CoV-2" exact="infection" post="leads to reduced generation of Ang 1â€&quot;7 and consequently,"/>
  <result pre="the kallikreinâ€&quot;kinin system (KKS), which ultimately leads to increases in" exact="vascular" post="permeability113,125. Indeed, several studies have documented that a tight"/>
  <result pre="to regulate the thromboresistance of endothelial cells126â€&quot;128. The reduction in" exact="pulmonary" post="ACE2 impairs the inactivation of des-Arg9 bradykinin (DABK), leaving"/>
  <result pre="changes in the surface expression of intracellular adhesion molecule-1 (ICAM1)," exact="vascular" post="cell adhesion protein-1 (VCAM1) and the tight junction scaffold"/>
  <result pre="reported by a preprint study135. Fig. 3 Effect of SARS-CoV-2" exact="infection" post="on endothelial cell function, systemic coagulation and thrombosis. a"/>
  <result pre="Fig. 3 Effect of SARS-CoV-2 infection on endothelial cell function," exact="systemic" post="coagulation and thrombosis. a | Severe acute respiratory syndrome"/>
  <result pre="on endothelial cell function, systemic coagulation and thrombosis. a |" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly infects endothelial"/>
  <result pre="endothelial cell function, systemic coagulation and thrombosis. a | Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) directly infects endothelial cells"/>
  <result pre="cell function, systemic coagulation and thrombosis. a | Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) directly infects endothelial cells owing"/>
  <result pre="function, systemic coagulation and thrombosis. a | Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) directly infects endothelial cells owing to"/>
  <result pre="receptor activation induces a pro-inflammatory phenotype through increased activation of" exact="type 1" post="angiotensin receptors (AT1R). Additionally, the reduction in levels of"/>
  <result pre="of complement activation. In addition, complexes of SARS-CoV-2-specific antibodies and" exact="viral" post="antigens might induce endothelial cell injury through activation of"/>
  <result pre="chemokines released by activated macrophages amplify the vicious cycle of" exact="vascular" post="integrity disruption, vessel coagulation and thrombosis by degrading the"/>
  <result pre="the vicious cycle of vascular integrity disruption, vessel coagulation and" exact="thrombosis" post="by degrading the endothelial glycocalyx, activating the coagulation system"/>
  <result pre="and clotting of red blood cells (RBCs), ultimately resulting in" exact="systemic" post="thrombosis and disseminated intravascular coagulation. However, the finding that"/>
  <result pre="clotting of red blood cells (RBCs), ultimately resulting in systemic" exact="thrombosis" post="and disseminated intravascular coagulation. However, the finding that viral"/>
  <result pre="red blood cells (RBCs), ultimately resulting in systemic thrombosis and" exact="disseminated intravascular coagulation." post="However, the finding that viral RNA is rarely detectable"/>
  <result pre="systemic thrombosis and disseminated intravascular coagulation. However, the finding that" exact="viral" post="RNA is rarely detectable in blood19 indicates that additional"/>
  <result pre="in blood19 indicates that additional host-dependent factors might contribute to" exact="systemic" post="endothelial dysfunction and vasculopathy in COVID-19, rather than direct"/>
  <result pre="that additional host-dependent factors might contribute to systemic endothelial dysfunction" exact="and vasculopathy" post="in COVID-19, rather than direct viral-dependent effects on endothelial"/>
  <result pre="pathogenic effects through various mechanisms. For example, IL-6 can increase" exact="vascular" post="permeability and promote the secretion of pro-inflammatory cytokines by"/>
  <result pre="and nitric oxide levels, as well as the release of" exact="vascular" post="endothelial growth factor (VEGF) as a consequence of the"/>
  <result pre="vascular endothelial growth factor (VEGF) as a consequence of the" exact="systemic" post="hypoxia induced by ARDS, have also been proposed as"/>
  <result pre="endothelial growth factor (VEGF) as a consequence of the systemic" exact="hypoxia" post="induced by ARDS, have also been proposed as key"/>
  <result pre="on the possible role of the complement system in inducing" exact="systemic" post="endothelial dysfunction in COVID-19. Excessive complement activation The complement"/>
  <result pre="complement, like other innate immune system components, helps to control" exact="bacterial" post="and viral infections, its unrestrained activation â€&quot; for example,"/>
  <result pre="other innate immune system components, helps to control bacterial and" exact="viral" post="infections, its unrestrained activation â€&quot; for example, in the"/>
  <result pre="activation â€&quot; for example, in the context of prolonged SARS-CoV-2" exact="infection" post="â€&quot; can be detrimental by causing direct damage of"/>
  <result pre="available data on complement activation in the context of coronavirus" exact="infection" post="are derived from the SARS and MERS epidemics. A"/>
  <result pre="demonstrated that C3-deficient mice experienced a less severe form of" exact="disease" post="than wild-type mice, associated with reduced lung infiltration of"/>
  <result pre="mice, associated with reduced lung infiltration of inflammatory cells and" exact="lower" post="hypercytokinaemia in both the lungs and sera139. SARS-CoV activates"/>
  <result pre="and inflammatory leukocytes, associated with strong C5bâ€&quot;9 deposition on bronchiolar" exact="epithelial" post="cells, pneumocytes and infiltrating leukocytes141. In line with these"/>
  <result pre="with strong C5bâ€&quot;9 deposition on bronchiolar epithelial cells, pneumocytes and" exact="infiltrating" post="leukocytes141. In line with these findings, immunohistochemistry analyses in"/>
  <result pre="the complement components MBL, C4, C3 and C5bâ€&quot;9, in alveolar" exact="epithelial" post="cells and pneumocytes, as well as in inflammatory cells,"/>
  <result pre="in patients with severe COVID-19 than in patients with mild" exact="disease" post="who had levels of C5a similar to those of"/>
  <result pre="injury induced by coronavirus infection. Indeed, immune complexes formed by" exact="viral" post="antigens and antibodies can activate C1 and initiate complement"/>
  <result pre="patients with SARS-CoV infection, the development of autoantibodies against human" exact="pulmonary" post="epithelial cells and endothelial cells mediated complement-dependent cytotoxicity143; however,"/>
  <result pre="with SARS-CoV infection, the development of autoantibodies against human pulmonary" exact="epithelial" post="cells and endothelial cells mediated complement-dependent cytotoxicity143; however, whether"/>
  <result pre="cytotoxicity143; however, whether this process is also activated following SARS-CoV-2" exact="infection" post="is unknown. Use of an ultra-high-throughput clinical proteomic approach"/>
  <result pre="from another study suggest that enhanced IgA levels during SARS-CoV-2" exact="infection" post="might act synergistically with IgG to promote antibody-dependent cytotoxicity108."/>
  <result pre="at least in part an IgA-mediated disease108, possibly inducing a" exact="vasculitis" post="phenotype via classical pathway-mediated cytotoxicity. Although clinical insights into"/>
  <result pre="pathway-mediated cytotoxicity. Although clinical insights into complement activation following SARS-CoV-2" exact="infection" post="are limited145, the above findings indicate that unrestrained complement"/>
  <result pre="the complement cascades â€&quot; may contribute to endothelial cell injury," exact="thrombosis" post="and intravascular coagulation, ultimately leading to multi-systemic organ failure"/>
  <result pre="organ failure in patients with COVID-19 (ref.137). Microangiopathy and vessel" exact="thrombosis" post="Activation of the complement system leads to endothelial cell"/>
  <result pre="system leads to endothelial cell injury and death with subsequent" exact="vascular" post="denudation and exposure of the thrombogenic basement membrane, which"/>
  <result pre="foci of alveolar haemorrhage147. In a larger series of post-mortem" exact="pulmonary" post="analyses in Northern Italy, a predominant finding was the"/>
  <result pre="â€&quot; fibrin thrombi in small arterial vessels, further suggesting that" exact="coagulopathy" post="has an important role in outcomes following SARS-CoV-2 infection148."/>
  <result pre="role in outcomes following SARS-CoV-2 infection148. Indeed, patients with SARS-CoV-2" exact="infection" post="are at an increased risk of widespread coagulation of"/>
  <result pre="and large vessels149, and venous thromboembolic complications â€&quot; in particular" exact="acute" post="pulmonary embolisms150â€&quot;153 â€&quot; are recognized as life-threatening complications in"/>
  <result pre="large vessels149, and venous thromboembolic complications â€&quot; in particular acute" exact="pulmonary" post="embolisms150â€&quot;153 â€&quot; are recognized as life-threatening complications in patients"/>
  <result pre="the deposition of blood clots in the microvasculature154 (Fig.Â 3)." exact="Kidney" post="involvement in COVID-19 The lungs are the main site"/>
  <result pre="in COVID-19 The lungs are the main site for SARS-CoV-2" exact="infection" post="and the first affected organ in COVID-19. However, sustained"/>
  <result pre="infection and the first affected organ in COVID-19. However, sustained" exact="viral" post="shedding and hyperactivation of the immune response in severe"/>
  <result pre="immune response in severe cases greatly increases the risk of" exact="systemic" post="multi-organ failure. Of the organs affected by COVID-19, the"/>
  <result pre="had proteinuria and 26.7% haematuria, whereas 5.1% of patients experienced" exact="acute" post="kidney injury (AKI) during the study156. Reports published later"/>
  <result pre="proteinuria and 26.7% haematuria, whereas 5.1% of patients experienced acute" exact="kidney injury" post="(AKI) during the study156. Reports published later in the"/>
  <result pre="is abundant or contains albumin, suggesting glomerular impairment158. Patients with" exact="kidney disease" post="are at a significantly higher risk of death than"/>
  <result pre="abundant or contains albumin, suggesting glomerular impairment158. Patients with kidney" exact="disease" post="are at a significantly higher risk of death than"/>
  <result pre="at a significantly higher risk of death than those without" exact="kidney disease," post="and elevated levels of baseline serum creatinine or blood"/>
  <result pre="and has been identified as a target organ for severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by several studies."/>
  <result pre="has been identified as a target organ for severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection by several studies. a"/>
  <result pre="been identified as a target organ for severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection by several studies. a |"/>
  <result pre="target organ for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="by several studies. a | Within the glomerulus, podocytes"/>
  <result pre="and endothelial cells have been identified as specific sites for" exact="viral infection." post="SARS-CoV-2-induced podocyte dysfunction is likely to induce impairment of"/>
  <result pre="and haematuria, which are often observed in patients with coronavirus" exact="disease" post="2019 (COVID-19). Infection of endothelial cells alters glomerular capillary"/>
  <result pre="are often observed in patients with coronavirus disease 2019 (COVID-19)." exact="Infection" post="of endothelial cells alters glomerular capillary haemostasis and induces"/>
  <result pre="high levels of ACE2 in the apical brush border. SARS-CoV-2" exact="infection" post="leads to loss of the brush border and vacuolar"/>
  <result pre="loss of the brush border and vacuolar degeneration in tubular" exact="epithelial" post="cells, with luminal debris composed of necrotic epithelium with"/>
  <result pre="a possible contribution of the APOL1 â€˜riskâ€™ genotype in inducing" exact="focal segmental glomerulosclerosis" post="following SARS-CoV-2 infection, as well as the role of"/>
  <result pre="contribution of the APOL1 â€˜riskâ€™ genotype in inducing focal segmental" exact="glomerulosclerosis" post="following SARS-CoV-2 infection, as well as the role of"/>
  <result pre="hypovolaemia, nephrotoxic drug treatments and nosocomial sepsis resulting in COVID-19-associated" exact="acute" post="kidney injury (AKI). In autopsy specimens, the spectrum of"/>
  <result pre="nephrotoxic drug treatments and nosocomial sepsis resulting in COVID-19-associated acute" exact="kidney injury" post="(AKI). In autopsy specimens, the spectrum of renal pathological"/>
  <result pre="loss of the brush border and vacuolar degeneration in tubular" exact="epithelial" post="cells, with debris composed of necrotic epithelium in tubular"/>
  <result pre="complications in patients with severe disease165. The relevance of microvascular" exact="thrombosis" post="in the kidney is still a matter of investigation."/>
  <result pre="is still a matter of investigation. One autopsy study identified" exact="limited" post="fibrin thrombi in glomerular capillaries of kidney specimens from"/>
  <result pre="been consistently found in the kidney and no significant glomerular" exact="disease" post="has been described, with the exception of collapsing focal"/>
  <result pre="glomerular disease has been described, with the exception of collapsing" exact="focal segmental glomerulosclerosis," post="which has been reported in a few patients and"/>
  <result pre="some patients with COVID-19 and imply that further insight into" exact="disease" post="pathogenesis may aid the identification of novel therapeutic targets"/>
  <result pre="changes that impair renal perfusion, and through the induction of" exact="systemic" post="inflammatory mediators as a consequence of ventilator-induced lung injury168."/>
  <result pre="SARS-CoV-2 may have a direct effect on kidney cells169â€&quot;172. Tubule" exact="epithelial" post="cells and podocytes exhibit high levels of ACE2 and"/>
  <result pre="that they are potential SARS-CoV-2 targets173,174. ACE2 internalization following SARS-CoV-2" exact="infection" post="could induce an imbalance in the reninâ€&quot;angiotensinâ€&quot;aldosterone system, with"/>
  <result pre="the kidney14,175. The critical role of ACE2 in SARS-CoV-2 kidney" exact="infection" post="is emphasized by findings from in vitro studies that"/>
  <result pre="that SARS-CoV-2 can infect human kidney organoids and that this" exact="infection" post="can be limited by expression of human recombinant soluble"/>
  <result pre="infect human kidney organoids and that this infection can be" exact="limited" post="by expression of human recombinant soluble ACE2 â€&quot; a"/>
  <result pre="26 patients who had died with COVID-19 demonstrated clusters of" exact="viral" post="particles in the tubular epithelium and podocytes163. Another study"/>
  <result pre="study that involved microdissection of autoptic tissue demonstrated detectable SARS-CoV-2" exact="viral" post="load in three of six deceased patients; within the"/>
  <result pre="SARS-CoV-2 or merely viral-like structures. In particular, the identification of" exact="viral" post="particles in kidney tissue by electron microscopy has been"/>
  <result pre="Moreover, studies of SARS-CoV-2 in biological fluids have rarely shown" exact="viral" post="shedding in the urine158, raising the possibility that a"/>
  <result pre="elegant study has documented enrichment of SARS-CoV-2 RNA in glomerular" exact="epithelial" post="and endothelial cells by in situ hybridization176. In line"/>
  <result pre="by in situ hybridization176. In line with this finding, active" exact="viral" post="replication in different tissues, including kidney tissue, was found"/>
  <result pre="not clear whether this renal active replication contributes to the" exact="viral" post="burden in the body. As described earlier, innate and"/>
  <result pre="to suggest that modulation of these processes in patients with" exact="kidney failure" post="may have consequences for disease outcomes. Despite some early"/>
  <result pre="processes in patients with kidney failure may have consequences for" exact="disease" post="outcomes. Despite some early small, uncontrolled studies showing the"/>
  <result pre="may have consequences for disease outcomes. Despite some early small," exact="uncontrolled" post="studies showing the opposite183,184, a report from Japan showed"/>
  <result pre="identify and repurpose therapeutics that are already available to attenuate" exact="viral" post="attachment and replication, hyperinflammation and the mechanisms underlying endothelial"/>
  <result pre="hyperinflammation and the mechanisms underlying endothelial damage, blood clotting and" exact="systemic" post="microangiopathy. Antiviral therapies The first week following SARS-CoV-2 infection"/>
  <result pre="and systemic microangiopathy. Antiviral therapies The first week following SARS-CoV-2" exact="infection" post="â€&quot; during which the virus enters alveolar cells and"/>
  <result pre="the lungs â€&quot; represents a critical time for blocking the" exact="infection" post="using antiviral agents. Of the repurposed antivirals investigated to"/>
  <result pre="SARS-CoV-2 RNA replication by competing with endogenous nucleotides for the" exact="viral" post="RdRp189. Despite initial, encouraging results190, the first placebo-controlled trial"/>
  <result pre="hydroxychloroquine has also been investigated for its ability to inhibit" exact="viral" post="infections200. However, available evidence does not support a beneficial"/>
  <result pre="hydroxychloroquine treatment poses serious safety concerns, increasing the risk of" exact="cardiovascular" post="death by more than twofold203,204. Given the lack of"/>
  <result pre="treatments for concurrent conditions. Targeting hyperinflammation In patients with adult-onset" exact="secondary" post="haemophagocytic lymphohistiocytosis, early intervention with corticosteroids is of utmost"/>
  <result pre="COVID-19 was initially discouraged because of the potential risk of" exact="secondary" post="infections, long-term complications and prolonged virus shedding207. However, early"/>
  <result pre="that a low to moderate dose of corticosteroids for a" exact="short" post="period could be effective during the early stages of"/>
  <result pre="early stages of the disease209,210. In randomized caseâ€&quot;control studies in" exact="adult" post="patients with severe community-acquired pneumonia, early and short-term (from"/>
  <result pre="of treatment failure211â€&quot;213. A preliminary study found that an early," exact="short" post="course of methylprednisolone therapy improved outcomes of adult patients"/>
  <result pre="an early, short course of methylprednisolone therapy improved outcomes of" exact="adult" post="patients with COVID-19 with moderate or severe disease214. In"/>
  <result pre="clinical trials of critically ill patients with COVID-19, use of" exact="systemic" post="corticosteroids was associated with lower 28-day all-cause mortality compared"/>
  <result pre="patients with COVID-19, use of systemic corticosteroids was associated with" exact="lower" post="28-day all-cause mortality compared with usual care or placebo215."/>
  <result pre="oxygen alone at randomization, but not among those receiving no" exact="respiratory" post="support216. These findings are encouraging since dexamethasone treatment is"/>
  <result pre="dexamethasone treatment is also highly beneficial in patients with pre-existing" exact="chronic" post="kidney disease217,218. Given the role of immune system hyperactivation"/>
  <result pre="For example, the observed suppression of interferon responses following SARS-CoV-2" exact="infection" post="suggests that interferon supplementation may be a potential therapeutic"/>
  <result pre="potential therapeutic approach for COVID-19, as it is for other" exact="infectious diseases" post="such as hepatitis. However, caution must be taken with"/>
  <result pre="interferon therapy, since interferon supplementation could induce or aggravate pre-existing" exact="autoimmune diseases" post="or induce life-threatening complications, such as kidney and/or cardiac"/>
  <result pre="induce life-threatening complications, such as kidney and/or cardiac impairment or" exact="pulmonary" post="interstitial fibrosis219. In addition, the finding that interferon stimulates"/>
  <result pre="addition, the finding that interferon stimulates expression of ACE2 in" exact="epithelial" post="tissues indicates that interferon therapy could potentially promote virus"/>
  <result pre="inhibit T cell effector functions in the early stages of" exact="viral" post="infection225,226. Thus, PD1 blockade with the use of immune"/>
  <result pre="may enhance the effector function of T cells and stimulate" exact="viral" post="clearance225,226. In patients with lung cancer, PD1-targeted immunotherapy increased"/>
  <result pre="of T cells and stimulate viral clearance225,226. In patients with" exact="lung cancer," post="PD1-targeted immunotherapy increased proliferation of PD1+ CD8+ T cells"/>
  <result pre="COVID-19 patients with severe lymphocytopenia was associated with a significantly" exact="lower" post="death rate and reduced need for invasive mechanical ventilation233."/>
  <result pre="endothelial dysfunction In light of the major contribution of widespread" exact="coagulopathy" post="and thrombosis to poor outcomes in COVID-19, the use"/>
  <result pre="In light of the major contribution of widespread coagulopathy and" exact="thrombosis" post="to poor outcomes in COVID-19, the use of prophylactic"/>
  <result pre="of IL-6 (ref.234). As recommended by the International Society on" exact="Thrombosis" post="and Haemostasis, the management of COVID-19- associated coagulopathy with"/>
  <result pre="Society on Thrombosis and Haemostasis, the management of COVID-19- associated" exact="coagulopathy" post="with LMWH should be accompanied by close monitoring of"/>
  <result pre="the prothrombin time for the early diagnosis of bleeding235, although" exact="bleeding" post="seems to be rare in patients with COVID-19 (ref.236)."/>
  <result pre="trials237â€&quot;240. This agent has short-acting anticoagulant effects and can limit" exact="viral infection" post="and replication by inhibiting TMPRSS2 (ref.241). That fact TMPPRSS2"/>
  <result pre="This agent has short-acting anticoagulant effects and can limit viral" exact="infection" post="and replication by inhibiting TMPRSS2 (ref.241). That fact TMPPRSS2"/>
  <result pre="prevented the progression of COVID-19 to severe stages of the" exact="disease" post="by significantly increasing platelet and lymphocyte counts and decreasing"/>
  <result pre="clinical data suggest that anti-coagulation therapies might have only a" exact="partial" post="effect on coagulopathy and thromboembolism in severe forms of"/>
  <result pre="that anti-coagulation therapies might have only a partial effect on" exact="coagulopathy" post="and thromboembolism in severe forms of the disease244. For"/>
  <result pre="A case report of a patient with COVID-19-associated ARDS and" exact="pneumonia" post="showed that treatment with a C3 inhibitor was safe"/>
  <result pre="activation of the entire complement cascade, halting the opsonization of" exact="viral" post="particles by C3b. Indeed, studies in knockout mice have"/>
  <result pre="is required for protection from the highly pathogenic H5N1 influenza" exact="infection" post="and proper viral clearance246, suggesting that C3 inhibition may"/>
  <result pre="protection from the highly pathogenic H5N1 influenza infection and proper" exact="viral" post="clearance246, suggesting that C3 inhibition may have undesirable consequences."/>
  <result pre="the three complement pathways, while still allowing C3 activation and" exact="viral" post="opsonization137. A 2015 study in an experimental model of"/>
  <result pre="experimental model of sepsis found that eculizumab significantly lowered consumptive" exact="coagulopathy" post="by inhibiting the formation of C5bâ€&quot;9, and by preventing"/>
  <result pre="represent an alternative therapeutic target. C5a stimulates cytokine release, increases" exact="vascular" post="permeability and induces the upregulation of adhesion molecules that"/>
  <result pre="(ref.142). Of note, C5 blockade has demonstrated benefit in various" exact="kidney diseases," post="including C3 glomerulopathy and atypical haemolytic uraemic syndrome251,252, suggesting"/>
  <result pre="demonstrated benefit in various kidney diseases, including C3 glomerulopathy and" exact="atypical" post="haemolytic uraemic syndrome251,252, suggesting that targeting complement might protect"/>
  <result pre="for breathing dysfunction and dyspnoea in patients with COVID-19 with" exact="pneumonia" post="and ARDS. However, despite fulfilling most of the criteria"/>
  <result pre="despite fulfilling most of the criteria of classic ARDS, COVID-19-associated" exact="pneumonia" post="may be a discrete disease characterized by two distinct"/>
  <result pre="criteria of classic ARDS, COVID-19-associated pneumonia may be a discrete" exact="disease" post="characterized by two distinct phenotypes253,254. In the early phase"/>
  <result pre="hypoxaemia induced by ARDS is often associated with near normal" exact="respiratory" post="system compliance253,254. In these patients, gentle oxygen therapy â€&quot;"/>
  <result pre="then either improve or suddenly deteriorate to a more severe" exact="disease" post="stage. In the latter situation, the resulting ARDS phenotype"/>
  <result pre="situation, the resulting ARDS phenotype is similar to that of" exact="acute" post="fibrinous and organizing pneumonia â€&quot; a rare form of"/>
  <result pre="phenotype is similar to that of acute fibrinous and organizing" exact="pneumonia" post="â€&quot; a rare form of acute lung injury that"/>
  <result pre="acute fibrinous and organizing pneumonia â€&quot; a rare form of" exact="acute" post="lung injury that differs from the diffuse alveolar damage"/>
  <result pre="rare form of acute lung injury that differs from the" exact="diffuse" post="alveolar damage found in classic forms of ARDS255. The"/>
  <result pre="a high level of positive end-expiratory pressure (PEEP)255,256. Indeed, if" exact="vascular" post="alterations, such as pulmonary vasoconstriction, pulmonary emboli or thrombi,"/>
  <result pre="positive end-expiratory pressure (PEEP)255,256. Indeed, if vascular alterations, such as" exact="pulmonary" post="vasoconstriction, pulmonary emboli or thrombi, are the major driver"/>
  <result pre="pressure (PEEP)255,256. Indeed, if vascular alterations, such as pulmonary vasoconstriction," exact="pulmonary" post="emboli or thrombi, are the major driver of hypoxaemia"/>
  <result pre="the response to PEEP differs on the basis of individual" exact="respiratory" post="mechanics29,30,257. This issue is of particular relevance for nephrologists,"/>
  <result pre="in the risk of AKI, and that patients with combined" exact="respiratory" post="failure and AKI have a mortality of 60â€&quot;80% in"/>
  <result pre="of 60â€&quot;80% in the ICU setting168. On the other hand," exact="acute" post="fibrinous and organizing pneumonia is a cortico-sensitive pathology and,"/>
  <result pre="ICU setting168. On the other hand, acute fibrinous and organizing" exact="pneumonia" post="is a cortico-sensitive pathology and, as described above, appropriate"/>
  <result pre="efficacy of this treatment as most data are derived from" exact="uncontrolled" post="case studies of patients with COVID-19. All case reports"/>
  <result pre="early after recovery from COVID-19. Second, patients with more severe" exact="disease" post="have higher antibody levels than patients with asymptomatic or"/>
  <result pre="extent of protection provided by antibodies in patients with severe" exact="disease" post="is unclear, and it might therefore be counterproductive to"/>
  <result pre="antibodies from convalescent patients. Conclusions Available evidence demonstrates that SARS-CoV-2" exact="infection" post="induces immune dysfunction, widespread endothelial injury, complement-associated coagulopathy and"/>
  <result pre="that SARS-CoV-2 infection induces immune dysfunction, widespread endothelial injury, complement-associated" exact="coagulopathy" post="and systemic microangiopathy. The clinical outcome of COVID-19 seems"/>
  <result pre="infection induces immune dysfunction, widespread endothelial injury, complement-associated coagulopathy and" exact="systemic" post="microangiopathy. The clinical outcome of COVID-19 seems to be"/>
  <result pre="response of the host. Although the contribution of differences in" exact="viral" post="loads to clinical outcome cannot be excluded271, it is"/>
  <result pre="predisposing genetic or biological factors may modulate the degree of" exact="disease" post="severity. Additionally, socioeconomic conditions and structural racism may contribute"/>
  <result pre="Additionally, socioeconomic conditions and structural racism may contribute to poor" exact="disease" post="outcomes in some regions, as demonstrated by disproportionately poor"/>
  <result pre="populations272. Improved insights into the mechanisms underlying predisposition to adverse" exact="disease" post="outcomes might aid the identification of new strategies and"/>
  <result pre="to prevent exacerbation of inflammatory and thrombotic processes and halt" exact="disease" post="progression. Given the spectrum of pathogenic mechanisms involved in"/>
  <result pre="of these pathogenic pathways, the multifactorial pathogenic nature of the" exact="disease" post="indicates that multiple avenues of treatment might be required"/>
  <result pre="enveloped, positive-strand RNA viruses that infects humans and mammals, causing" exact="respiratory" post="diseases that can be mild or severe. RNA-dependent RNA"/>
  <result pre="or severe. RNA-dependent RNA polymerase (RdRp). An enzyme encoded by" exact="viral" post="RNA that catalyses the synthesis of new RNA strands"/>
  <result pre="strands complementary to the initial RNA template included in the" exact="viral" post="capsid. Incubation period The number of days between the"/>
  <result pre="infected individual experiences the first symptoms of the disease. Anosmia" exact="Complete" post="loss of the ability to detect one or more"/>
  <result pre="or permanent such as occurs in certain neurological conditions. Ageusia" exact="Complete" post="loss of taste on the tongue, particularly the inability"/>
  <result pre="molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) generated during" exact="infections" post="or injury. Cytokine storm Also called hypercytokinaemia. An excessive"/>
  <result pre="or injury. Cytokine storm Also called hypercytokinaemia. An excessive and" exact="uncontrolled" post="release of pro-inflammatory molecules by the cellular components of"/>
  <result pre="the innate immune system in response to a number of" exact="infectious" post="and non-infectious aetiologies that can lead to multi-organ damage"/>
  <result pre="diversity (D), joining (J) and constant (C) genes at three" exact="primary" post="loci in the human genome and undergoes somatic rearrangements"/>
  <result pre="References References 1.AndersenKGRambautALipkinWIHolmesECGarryRFThe proximal origin of SARS-CoV-2Nat. Med.2020645045210.1038/s41591-020-0820-9 2.ZhouPet al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="16.XuHet al.High expression of ACE2 receptor of 2019-nCoV on the" exact="epithelial" post="cells of oral mucosaInt. J. Oral. Sci.2020121510.1038/s41368-019-0067-931900382 17.SungnakWet al.SARS-CoV-2"/>
  <result pre="Sci.2020121510.1038/s41368-019-0067-931900382 17.SungnakWet al.SARS-CoV-2 entry factors are highly expressed in nasal" exact="epithelial" post="cells together with innate immune genesNat. Med.20202668168710.1038/s41591-020-0868-632327758 18.ZieglerCGKet al.SARS-CoV-2"/>
  <result pre="al.SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway" exact="epithelial" post="cells and is detected in specific cell subsets across"/>
  <result pre="Engl. J. Med.20203821199120710.1056/NEJMoa200131631995857 21.HouYJet al.SARS-CoV-2 reverse genetics reveals a variable" exact="infection" post="gradient in the respiratory tractCell2020182429446.e1410.1016/j.cell.2020.05.04232526206 22.ShiYet al.COVID-19 infection: the"/>
  <result pre="al.SARS-CoV-2 reverse genetics reveals a variable infection gradient in the" exact="respiratory" post="tractCell2020182429446.e1410.1016/j.cell.2020.05.04232526206 22.ShiYet al.COVID-19 infection: the perspectives on immune responsesCell"/>
  <result pre="23.CaoXCOVID-19: immunopathology and its implications for therapyNat.Rev. Immunol.20202026927010.1038/s41577-020-0308-332273594 24.AckermannMet al.Pulmonary" exact="vascular" post="endothelialitis, thrombosis, and angiogenesis in Covid-19N. Engl. J. Med.202038312012810.1056/NEJMoa201543232437596"/>
  <result pre="COVID-19 diseaseInt. J. Legal Med.2020341271127410.1007/s00414-020-02318-9 26.PernazzaAet al.Early histologic findings of" exact="pulmonary" post="SARS-CoV-2 infection detected in a surgical specimenVirchows Arch.202010.1007/s00428-020-02829-132915266 27.HuangCet"/>
  <result pre="J. Legal Med.2020341271127410.1007/s00414-020-02318-9 26.PernazzaAet al.Early histologic findings of pulmonary SARS-CoV-2" exact="infection" post="detected in a surgical specimenVirchows Arch.202010.1007/s00428-020-02829-132915266 27.HuangCet al.Clinical features"/>
  <result pre="in Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 28.XuZet al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.2020842042210.1016/S2213-2600(20)30076-X32085846 29.FanEet al.COVID-19-associated acute respiratory"/>
  <result pre="Wuhan, ChinaLancet202039549750610.1016/S0140-6736(20)30183-531986264 28.XuZet al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.2020842042210.1016/S2213-2600(20)30076-X32085846 29.FanEet al.COVID-19-associated acute respiratory distress"/>
  <result pre="associated with acute respiratory distress syndromeLancet Respir. Med.2020842042210.1016/S2213-2600(20)30076-X32085846 29.FanEet al.COVID-19-associated" exact="acute" post="respiratory distress syndrome: is a different approach to management"/>
  <result pre="with acute respiratory distress syndromeLancet Respir. Med.2020842042210.1016/S2213-2600(20)30076-X32085846 29.FanEet al.COVID-19-associated acute" exact="respiratory" post="distress syndrome: is a different approach to management warranted?Lancet"/>
  <result pre="different approach to management warranted?Lancet Respir. Med.2020881682110.1016/S2213-2600(20)30304-032645311 30.MariniJJGattinoniLManagement of COVID-19" exact="respiratory" post="distressJAMA20203232329233010.1001/jama.2020.682532329799 31.PatelAet al.New onset anosmia and ageusia in adult"/>
  <result pre="COVID-19 respiratory distressJAMA20203232329233010.1001/jama.2020.682532329799 31.PatelAet al.New onset anosmia and ageusia in" exact="adult" post="patients diagnosed with SARS-CoV-2Clin. Microbiol. Infect.2020261236124110.1016/j.cmi.2020.05.0267265826 32.Romero-SÃ¡nchezCMet al.Neurologic manifestations"/>
  <result pre="manifestations in hospitalized patients with COVID-19: The ALBACOVID registryNeurology202095e1060e107010.1212/WNL.000000000000993732482845 33.DockeryDMRoweSGMurphyMAKrzystolikMGThe" exact="ocular" post="manifestations and transmission of COVID-19: recommendations for preventionJ. Emerg."/>
  <result pre="al.Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected" exact="disease" post="2019 (COVID-19) with gastrointestinal symptomsGut2020691002100910.1136/gutjnl-2020-32092632213556 36.ShiSet al.Association of cardiac"/>
  <result pre="in Wuhan, ChinaJAMA Cardiol.2020580281010.1001/jamacardio.2020.095032211816 37.ZangRet al.TMPRSS2 and TMPRSS4 promote SARS-CoV-2" exact="infection" post="of human small intestinal enterocytesSci. Immunol.20205eabc358210.1126/sciimmunol.abc358232404436 38.LamersMMet al.SARS-CoV-2 productively"/>
  <result pre="link between SARS-CoV-2 and the eye?: ACE2 expression on the" exact="ocular" post="surfaceJ. Med. Virol.202010.1002/jmv.2613632497334 40.LucasCet al.Longitudinal analyses reveal immunological misfiring"/>
  <result pre="COVID-19Nature202058446346910.1038/s41586-020-2588-y32717743 41.Giamarellos-BourboulisEJet al.Complex immune dysregulation in COVID-19 patients with severe" exact="respiratory" post="failureCell Host Microbe2020279921000.e310.1016/j.chom.2020.04.00932320677 42.MathewDet al.Deep immune profiling of COVID-19"/>
  <result pre="response to SARS-CoV-2 drives development of COVID-19Cell202018110361045.e910.1016/j.cell.2020.04.02632416070 46.ParkAIwasakiAType I. and" exact="type III" post="interferons â€&quot; induction, signaling, evasion, and application to combat"/>
  <result pre="by the Nsp1 protein of SARS-CoV-2Science20203691249125510.1126/science.abc866532680882 48.JiangHet al.SARS-CoV-2 Orf9b suppresses" exact="type I" post="interferon responses by targeting TOM70Cell. Mol. Immunol.202017998100010.1038/s41423-020-0514-832728199 49.VazquezCHornerSMMAVS coordination"/>
  <result pre="protein interaction map reveals targets for drug repurposingNature202058345946810.1038/s41586-020-2286-932353859 51.HadjadjJet al.Impaired" exact="type I" post="interferon activity and inflammatory responses in severe COVID-19 patientsScience202036971872410.1126/science.abc602732661059"/>
  <result pre="54.YangYet al.Plasma IP-10 and MCP-3 levels are highly associated with" exact="disease" post="severity and predict the progression of COVID-19J. Allergy Clin."/>
  <result pre="Haematol.201316160962210.1111/bjh.1229323577835 56.McGonagleDSharifKOâ€™ReganABridgewoodCThe role of cytokines including interleukin-6 in COVID-19 induced" exact="pneumonia" post="and macrophage activation syndrome-like diseaseAutoimmun. Rev.20201910253710.1016/j.autrev.2020.10253732251717 57.SinhaPMatthayMACalfeeCSIs a â€œcytokine"/>
  <result pre="immune cells in patients with COVID-19Nat. Med.20202684284410.1038/s41591-020-0901-932398875 61.B BostPet al.Host-viral" exact="infection" post="maps reveal signatures of severe COVID-19 patientsCell202018114751488.e1210.1016/j.cell.2020.05.00632479746 62.ShenBet al.Proteomic"/>
  <result pre="C. R. in Apolipoprotein Mimetics in the Management of Human" exact="Disease" post="(eds Anantharamaiah, G., Goldberg, D.)(Adis, Springer International Publishing, 2015)."/>
  <result pre="SARS-CoV-2 pathogenesisMed202010.1016/j.medj.2020.07.00233043313 65.Z ZhouZet al.Heightened innate immune responses in the" exact="respiratory" post="tract of COVID-19 patientsCell Host Microbe202027883890.e210.1016/j.chom.2020.04.01732407669 66.WangDet al.Clinical characteristics"/>
  <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA20203231061106910.1001/jama.2020.158532031570 67.Liu, J. et al. Neutrophil-to-lymphocyte ratio"/>
  <result pre="70.ChenGet al.Clinical and immunological features of severe and moderate coronavirus" exact="disease" post="2019J. Clin. Invest.20201302620262910.1172/JCI13724432217835 71.YangXet al.Clinical course and outcomes of"/>
  <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir."/>
  <result pre="retrospective, observational studyLancet Respir. Med.2020847548110.1016/S2213-2600(20)30079-532105632 72.TanLet al.Validation of predictors of" exact="disease" post="severity and outcomes in COVID-19 patients: a descriptive and"/>
  <result pre="and functional exhaustion of T cells in patients with coronavirus" exact="disease" post="2019 (COVID-19)Front. Immunol.20201182710.3389/fimmu.2020.0082732425950 75.Chen, Y. et al. The novel"/>
  <result pre="2019 (COVID-19)Front. Immunol.20201182710.3389/fimmu.2020.0082732425950 75.Chen, Y. et al. The novel severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens"/>
  <result pre="(COVID-19)Front. Immunol.20201182710.3389/fimmu.2020.0082732425950 75.Chen, Y. et al. The novel severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and"/>
  <result pre="Immunol.20201182710.3389/fimmu.2020.0082732425950 75.Chen, Y. et al. The novel severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph"/>
  <result pre="medRxiv10.1101/2020.03.27.20045427 (2020). 76.BellesiSet al.Increased CD95 (Fas) and PD-1 expression in" exact="peripheral" post="blood T lymphocytes in COVID-19 patientsBr. J.Haematol.202010.1111/bjh.1703432679621 77.QinCet al.Dysregulation"/>
  <result pre="with COVID-19 in Wuhan, ChinaClin. Infect. Dis.20207176276810.1093/cid/ciaa24832161940 78.Bermejo-MartinJFet al.Lymphopenic community" exact="acquired" post="pneumonia as signature of severe COVID-19 infectionJ. Infect.202080e23e2410.1016/j.jinf.2020.02.02932145214 79.Bermejo-MartinJFet"/>
  <result pre="COVID-19 in Wuhan, ChinaClin. Infect. Dis.20207176276810.1093/cid/ciaa24832161940 78.Bermejo-MartinJFet al.Lymphopenic community acquired" exact="pneumonia" post="as signature of severe COVID-19 infectionJ. Infect.202080e23e2410.1016/j.jinf.2020.02.02932145214 79.Bermejo-MartinJFet al.Lymphopenic"/>
  <result pre="as signature of severe COVID-19 infectionJ. Infect.202080e23e2410.1016/j.jinf.2020.02.02932145214 79.Bermejo-MartinJFet al.Lymphopenic community" exact="acquired" post="pneumonia (L-CAP), an immunological phenotype associated with higher risk"/>
  <result pre="signature of severe COVID-19 infectionJ. Infect.202080e23e2410.1016/j.jinf.2020.02.02932145214 79.Bermejo-MartinJFet al.Lymphopenic community acquired" exact="pneumonia" post="(L-CAP), an immunological phenotype associated with higher risk of"/>
  <result pre="immunological phenotype associated with higher risk of mortalityEBioMedicine20172423123610.1016/j.ebiom.2017.09.02328958655 80.MenÃ©ndezRet al.simultaneous" exact="depression" post="of immunological synapse and endothelial injury is associated with"/>
  <result pre="T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19" exact="disease" post="and unexposed individualsCell202018114891501.e1510.1016/j.cell.2020.05.01532473127 82.PengYet al.Broad and strong memory CD4"/>
  <result pre="and kinetics of SARS-CoV-2â€&quot;specific T cells in COVID-19 patients with" exact="acute" post="respiratory distress syndromeSci. Immunol.20205eabd207110.1126/sciimmunol.abd207132591408 85.BraunJet al.SARS-CoV-2-reactive T cells in"/>
  <result pre="kinetics of SARS-CoV-2â€&quot;specific T cells in COVID-19 patients with acute" exact="respiratory" post="distress syndromeSci. Immunol.20205eabd207110.1126/sciimmunol.abd207132591408 85.BraunJet al.SARS-CoV-2-reactive T cells in healthy"/>
  <result pre="of human single-domain antibodies against SARS-CoV-2Cell Host Microbe202027891898.e510.1016/j.chom.2020.04.02332413276 92.ChandrashekarAet al.SARS-CoV-2" exact="infection" post="protects against rechallenge in rhesus macaquesScience202036981281710.1126/science.abc477632434946 93.DengWet al.Primary exposure"/>
  <result pre="a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with" exact="limited" post="somatic mutationImmunity20205398105.e510.1016/j.immuni.2020.06.00132561270 100.JunoJAet al.Humoral and circulating follicular helper T"/>
  <result pre="with severe COVID-19Sci. Immunol.20205eabd711410.1126/sciimmunol.abd711432669287 103.WilkAJet al.A single-cell atlas of the" exact="peripheral" post="immune response in patients with severe COVID-19Nat. Med.2020261070107610.1038/s41591-020-0944-y32514174 104.Woodruff,"/>
  <result pre="spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and" exact="disease" post="severityEBioMedicine20205810291110.1016/j.ebiom.2020.10291132711254 106.Wu, F. et al. Neutralizing antibody responses to"/>
  <result pre="implications. Preprint at medRxiv10.1101/2020.03.30.20047365 (2020). 107.LiuLet al.Anti-spike IgG causes severe" exact="acute" post="lung injury by skewing macrophage responses during acute SARS-CoV"/>
  <result pre="causes severe acute lung injury by skewing macrophage responses during" exact="acute" post="SARS-CoV infectionJCI Insight20194e12315810.1172/jci.insight.123158 108.YuHet al.Distinct features of SARS-CoV-2-specific IgA"/>
  <result pre="Arch.200745434535910.1007/s00424-007-0212-817256154 113.TeuwenLAGeldhofVPasutACarmelietPCOVID-19: the vasculature unleashedNat. Rev. Immunol.20202038939110.1038/s41577-020-0343-032439870 114.VargaZet al.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet20203951417141810.1016/S0140-6736(20)30937-532325026 115.OxleyTJet al.Large-vessel stroke as a"/>
  <result pre="114.VargaZet al.Endothelial cell infection and endotheliitis in COVID-19Lancet20203951417141810.1016/S0140-6736(20)30937-532325026 115.OxleyTJet al.Large-vessel" exact="stroke" post="as a presenting feature of covid-19 in the YoungN."/>
  <result pre="Engl. J. Med.2020382e6010.1056/NEJMc200978732343504 116.Cheng. M. European Doctors Warn Rare Kidsâ€™" exact="Syndrome" post="May Have Virus Tie. (Associated Press, 2020). 117.BunyavanichSDoAVicencioANasal gene"/>
  <result pre="118.RiphagenSGomezXGonzalez-MartinezCWilkinsonNTheocharisPHyperinflammatory shock in children during COVID-19 pandemicLancet20203951607160810.1016/S0140-6736(20)31094-132386565 119.DiorioCet al.Multisystem inflammatory" exact="syndrome" post="in children and COVID-19 are distinct presentations of SARS-CoV-2J."/>
  <result pre="are distinct presentations of SARS-CoV-2J. Clin. Invest.202010.1172/JCI14097032730233 120.CheungEWet al.Multisystem inflammatory" exact="syndrome" post="related to COVID-19 in previously healthy children and adolescents"/>
  <result pre="in New York CityJAMA202032429429610.1001/jama.2020.1037432511676 121.VerdoniLet al.An outbreak of severe Kawasaki-like" exact="disease" post="at the Italian epicentre of the SARS-CoV-2 epidemic: an"/>
  <result pre="of the SARS-CoV-2 epidemic: an observational cohort studyLancet20203951771177810.1016/S0140-6736(20)31103-X32410760 122.ZahraBet al.Acute" exact="heart" post="failure in multisystem inflammatory syndrome in children (MIS-C) in"/>
  <result pre="observational cohort studyLancet20203951771177810.1016/S0140-6736(20)31103-X32410760 122.ZahraBet al.Acute heart failure in multisystem inflammatory" exact="syndrome" post="in children (MIS-C) in the context of global SARS-CoV-2"/>
  <result pre="the context of global SARS-CoV-2 pandemicCirculation202010.1161/CIRCULATIONAHA.120.048360 123.MonteilVet al.Inhibition of SARS-CoV-2" exact="Infections" post="in engineered human tissues using clinical-grade soluble human ACE2Cell2020181905913.e710.1016/j.cell.2020.04.00432333836"/>
  <result pre="using clinical-grade soluble human ACE2Cell2020181905913.e710.1016/j.cell.2020.04.00432333836 124.VerdecchiaPCavalliniCSpanevelloAAngeliFThe pivotal link between ACE2" exact="deficiency" post="and SARS-CoV-2 infectionEur. J. Intern. Med.202076142010.1016/j.ejim.2020.04.03732336612 125.GarvinMRet al.A mechanistic"/>
  <result pre="receptors of the kallikrein/kinin and reninâ€&quot;angiotensin systemsFront. Med.201636110.3389/fmed.2016.00061 128.StavrouEXet al.Reduced" exact="thrombosis" post="in Klkb1âˆ’/âˆ’ mice is mediated by increased Mas receptor,"/>
  <result pre="Sirt1, and KLF4 and decreased tissue factorBlood201512571071910.1182/blood-2014-01-55028525339356 129.SodhiCPet al.Attenuation of" exact="pulmonary" post="ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and"/>
  <result pre="ARB and ACEI controversyEBioMedicine20205810290710.1016/j.ebiom.2020.10290732771682 131.FangCet al.Angiotensin 1-7 and Mas decrease" exact="thrombosis" post="in Bdkrb2âˆ’/âˆ’ mice by increasing NO and prostacyclin to"/>
  <result pre="de VeerdonkFLet al.Kallikrein-kinin blockade in patients with COVID-19 to prevent" exact="acute" post="respiratory distress syndromeeLife20209e5755510.7554/eLife.5755532338605 134.RocheJARocheRA hypothesized role for dysregulated bradykinin"/>
  <result pre="VeerdonkFLet al.Kallikrein-kinin blockade in patients with COVID-19 to prevent acute" exact="respiratory" post="distress syndromeeLife20209e5755510.7554/eLife.5755532338605 134.RocheJARocheRA hypothesized role for dysregulated bradykinin signaling"/>
  <result pre="syndromeeLife20209e5755510.7554/eLife.5755532338605 134.RocheJARocheRA hypothesized role for dysregulated bradykinin signaling in COVID-19" exact="respiratory" post="complicationsFASEB J.2020347265726910.1096/fj.20200096732359101 135.Buzhdygan, T. P. et al. The SARS-CoV-2"/>
  <result pre="and complementJ. Clin. Invest.20201303950395310.1172/JCI13076732459663 139.GralinskiLEet al.Complement activation contributes to severe" exact="acute" post="respiratory syndrome coronavirus pathogenesismBio20189e017531810.1128/mBio.01753-1830301856 140.IpWKEet al.Mannose-binding lectin in severe"/>
  <result pre="complementJ. Clin. Invest.20201303950395310.1172/JCI13076732459663 139.GralinskiLEet al.Complement activation contributes to severe acute" exact="respiratory" post="syndrome coronavirus pathogenesismBio20189e017531810.1128/mBio.01753-1830301856 140.IpWKEet al.Mannose-binding lectin in severe acute"/>
  <result pre="Clin. Invest.20201303950395310.1172/JCI13076732459663 139.GralinskiLEet al.Complement activation contributes to severe acute respiratory" exact="syndrome" post="coronavirus pathogenesismBio20189e017531810.1128/mBio.01753-1830301856 140.IpWKEet al.Mannose-binding lectin in severe acute respiratory"/>
  <result pre="acute respiratory syndrome coronavirus pathogenesismBio20189e017531810.1128/mBio.01753-1830301856 140.IpWKEet al.Mannose-binding lectin in severe" exact="acute" post="respiratory syndrome coronavirus infectionJ. Infect. Dis.20051911697170410.1086/42963115838797 141.JiangYet al.Blockade of"/>
  <result pre="respiratory syndrome coronavirus pathogenesismBio20189e017531810.1128/mBio.01753-1830301856 140.IpWKEet al.Mannose-binding lectin in severe acute" exact="respiratory" post="syndrome coronavirus infectionJ. Infect. Dis.20051911697170410.1086/42963115838797 141.JiangYet al.Blockade of the"/>
  <result pre="syndrome coronavirus pathogenesismBio20189e017531810.1128/mBio.01753-1830301856 140.IpWKEet al.Mannose-binding lectin in severe acute respiratory" exact="syndrome" post="coronavirus infectionJ. Infect. Dis.20051911697170410.1086/42963115838797 141.JiangYet al.Blockade of the C5a-C5aR"/>
  <result pre="complement over-activation. Preprint at medRxiv10.1101/2020.03.29.20041962 (2020). 143.YangYHet al.Autoantibodies against human" exact="epithelial" post="cells and endothelial cells after severe acute respiratory syndrome"/>
  <result pre="al.Autoantibodies against human epithelial cells and endothelial cells after severe" exact="acute" post="respiratory syndrome (SARS)-associated coronavirus infectionJ. Med. Virol.2005771710.1002/jmv.2040716032747 144.MessnerCBet al.Ultra-high-throughput"/>
  <result pre="against human epithelial cells and endothelial cells after severe acute" exact="respiratory" post="syndrome (SARS)-associated coronavirus infectionJ. Med. Virol.2005771710.1002/jmv.2040716032747 144.MessnerCBet al.Ultra-high-throughput clinical"/>
  <result pre="human epithelial cells and endothelial cells after severe acute respiratory" exact="syndrome" post="(SARS)-associated coronavirus infectionJ. Med. Virol.2005771710.1002/jmv.2040716032747 144.MessnerCBet al.Ultra-high-throughput clinical proteomics"/>
  <result pre="as a target in COVID-19?Nat. Rev. Immunol.20202034334410.1038/s41577-020-0320-732327719 146.McGonagleDOâ€™DonnellJSSharifKEmeryPBridgewoodCImmune mechanisms of" exact="pulmonary" post="intravascular coagulopathy in COVID-19 pneumoniaLancet Rheumatol.20202e437e44510.1016/S2665-9913(20)30121-132835247 147.Fox, S. E."/>
  <result pre="target in COVID-19?Nat. Rev. Immunol.20202034334410.1038/s41577-020-0320-732327719 146.McGonagleDOâ€™DonnellJSSharifKEmeryPBridgewoodCImmune mechanisms of pulmonary intravascular" exact="coagulopathy" post="in COVID-19 pneumoniaLancet Rheumatol.20202e437e44510.1016/S2665-9913(20)30121-132835247 147.Fox, S. E. et al."/>
  <result pre="coagulopathy in COVID-19 pneumoniaLancet Rheumatol.20202e437e44510.1016/S2665-9913(20)30121-132835247 147.Fox, S. E. et al." exact="Pulmonary" post="and cardiac pathology in Covid-19: the first autopsy series"/>
  <result pre="New Orleans. Preprint at medRxiv10.1101/2020.04.06.20050575 (2020). 148.Carsana, L. et al." exact="Pulmonary" post="post-mortem findings in a large series of COVID-19 cases"/>
  <result pre="prognosis in patients with novel coronavirus pneumoniaJ. Thromb. Haemost.20201884484710.1111/jth.1476832073213 150.DanziGBLoffiMGaleazziGGherbesiEAcute" exact="pulmonary embolism" post="and COVID-19 pneumonia: a random association?Eur. Heart J.202041185810.1093/eurheartj/ehaa25432227120 151.LlitjosJFet"/>
  <result pre="Haemost.20201884484710.1111/jth.1476832073213 150.DanziGBLoffiMGaleazziGGherbesiEAcute pulmonary embolism and COVID-19 pneumonia: a random association?Eur." exact="Heart" post="J.202041185810.1093/eurheartj/ehaa25432227120 151.LlitjosJFet al.High incidence of venous thromboembolic events in"/>
  <result pre="in anticoagulated severe COVID-19 patientsJ. Thromb. Haemost.2020181743174610.1111/jth.1486932320517 152.ZuckierLSMoadelRMHaramatiLBFreemanLDiagnostic evaluation of" exact="pulmonary embolism" post="during the COVID-19 pandemicJ. Nucl. Med.20206163063110.2967/jnumed.120.24557132238427 153.BeunRKusadasiNSikmaMWesterinkJHuismanAThromboembolic events and"/>
  <result pre="155.RadermeckerCet al.Neutrophil extracellular traps infiltrate the lung airway, interstitial, and" exact="vascular" post="compartments in severe COVID-19J. Exp. Med.2020217e2020101210.1084/jem.2020101232926097 156.ChengYet al.Kidney disease"/>
  <result pre="and vascular compartments in severe COVID-19J. Exp. Med.2020217e2020101210.1084/jem.2020101232926097 156.ChengYet al.Kidney" exact="disease" post="is associated with in-hospital death of patients with COVID-19Kidney"/>
  <result pre="with in-hospital death of patients with COVID-19Kidney Int.20209782983810.1016/j.kint.2020.03.00532247631 157.GabarrePet al.Acute" exact="kidney injury" post="in critically ill patients with COVID-19Intensive Care Med.2020461339134810.1007/s00134-020-06153-932533197 158.ChanLet"/>
  <result pre="patients with COVID-19J. Am. Soc. Nephrol.202010.1681/ASN.202005061532900843 159.AliHet al.Survival rate in" exact="acute" post="kidney injury superimposed COVID-19 patients: a systematic review and"/>
  <result pre="with COVID-19J. Am. Soc. Nephrol.202010.1681/ASN.202005061532900843 159.AliHet al.Survival rate in acute" exact="kidney injury" post="superimposed COVID-19 patients: a systematic review and meta-analysisRen. Fail.20204239339710.1080/0886022X.2020.175632332340507"/>
  <result pre="Fail.20204239339710.1080/0886022X.2020.175632332340507 160.LimJ-Het al.Fatal outcomes of COVID-19 in patients with severe" exact="acute" post="kidney injuryJ. Clin. Med.20209171810.3390/jcm90617187355571 161.collab: Division of Nephrology, Columbia"/>
  <result pre="of PhysiciansDisaster Response to the COVID-19 Pandemic for Patients with" exact="Kidney" post="Disease in New York CityJ. Am. Soc. Nephrol.2020311371137910.1681/ASN.202004052032499395 162.AlbericiFet"/>
  <result pre="PhysiciansDisaster Response to the COVID-19 Pandemic for Patients with Kidney" exact="Disease" post="in New York CityJ. Am. Soc. Nephrol.2020311371137910.1681/ASN.202004052032499395 162.AlbericiFet al.Management"/>
  <result pre="COVID-19 in ChinaKidney Int.20209821922710.1016/j.kint.2020.04.00332327202 164.MagroCet al.Complement associated microvascular injury and" exact="thrombosis" post="in the pathogenesis of severe COVID-19 infection: a report"/>
  <result pre="et al. Human kidney is a target for novel severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Preprint at medRxiv10.1101/2020.03.04.20031120"/>
  <result pre="al. Human kidney is a target for novel severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection. Preprint at medRxiv10.1101/2020.03.04.20031120 (2020)."/>
  <result pre="Human kidney is a target for novel severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection. Preprint at medRxiv10.1101/2020.03.04.20031120 (2020). 166.LarsenCPBourneTDWilsonJDSaqqaOSharshirMA."/>
  <result pre="167.MagoonSet al.COVID-19â€&quot;related glomerulopathy: a report of 2 cases of collapsing" exact="focal" post="segmental glomerulosclerosisKidney Med.2020248849210.1016/j.xkme.2020.05.00432775989 168.HepokoskiMLMalhotraASinghPCrotty AlexanderLEVentilator-induced kidney injury: are novel"/>
  <result pre="injury: are novel biomarkers the key to prevention?Nephron2018140909310.1159/00049155729996132 169.DurvasulaRWellingtonTMcNamaraEWatnickSCOVID-19 and" exact="kidney failure" post="in the acute care setting: our experience from SeattleAm."/>
  <result pre="the key to prevention?Nephron2018140909310.1159/00049155729996132 169.DurvasulaRWellingtonTMcNamaraEWatnickSCOVID-19 and kidney failure in the" exact="acute" post="care setting: our experience from SeattleAm. J. Kidney Dis.2020764610.1053/j.ajkd.2020.04.00132276031"/>
  <result pre="in the acute care setting: our experience from SeattleAm. J." exact="Kidney" post="Dis.2020764610.1053/j.ajkd.2020.04.00132276031 170.NaickerSet al.The novel coronavirus 2019 epidemic and kidneysKidney"/>
  <result pre="2019 epidemic and kidneysKidney Int.20209782482810.1016/j.kint.2020.03.00132204907 171.FarkashEAWilsonAMJentzenJMUltrastructural evidence for direct renal" exact="infection" post="with SARS-CoV-2J. Am. Soc. Nephrol.2020311683168710.1681/ASN.202004043232371536 172.AbbateMRottoliDGianattiACOVID-19 attacks the kidney:"/>
  <result pre="the glomerular epitheliumNephron202014434134210.1159/00050843032512569 173.XuDet al.Identification of a potential mechanism of" exact="acute" post="kidney injury during the COVID-19 outbreak: a study based"/>
  <result pre="glomerular epitheliumNephron202014434134210.1159/00050843032512569 173.XuDet al.Identification of a potential mechanism of acute" exact="kidney injury" post="during the COVID-19 outbreak: a study based on single-cell"/>
  <result pre="kidney biopsy findingsJ. Am. Soc. Nephrol.2020311948195810.1681/ASN.202005069932660970 182.HanleyBet al.Histopathological findings and" exact="viral" post="tropism in UK patients with severe fatal COVID-19: a"/>
  <result pre="post-mortem studyLancet Microbe202010.1016/S2666-5247(20)30115-432844161 183.Ma, Y. et al. 2019 novel coronavirus" exact="disease" post="in hemodialysis (HD) patients: Report from one HD center"/>
  <result pre="al.COVID-19 in hemodialysis patients: a report of 5 casesAm. J." exact="Kidney" post="Dis.20207614114310.1053/j.ajkd.2020.03.00932240718 185.KikuchiKet al.COVID-19 in dialysis patients in Japan: current"/>
  <result pre="and MERS vaccine developmentTransbound Emerg. Dis.202010.1111/tbed.1380432815655 189.ShannonAet al.Remdesivir and SARS-CoV-2:" exact="Structural" post="requirements at both nsp12 RdRp and nsp14 exonuclease active-sitesAntivir."/>
  <result pre="of coronavirus spike proteins and host ACE2 receptors predict potential" exact="intermediate" post="hosts of SARS-CoV-2J. Med. Virol.20209259560110.1002/jmv.2572632100877 191.WangYet al.Remdesivir in adults"/>
  <result pre="al.Threatening drug-drug interaction in a kidney transplant patient with Coronavirus" exact="Disease" post="2019 (COVID-19)Transpl. Infect. Dis.202022e1328610.1111/tid.1328632279418 200.VincentMJet al.Chloroquine is a potent"/>
  <result pre="Dis.202022e1328610.1111/tid.1328632279418 200.VincentMJet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 201.CavalcantiABet al.Hydroxychloroquine with or without azithromycin"/>
  <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical"/>
  <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA"/>
  <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA Netw."/>
  <result pre="2 (SARS-CoV-2) infection: a randomized clinical trialJAMA Netw. Open20203e20885710.1001/jamanetworkopen.2020.885732330277 205.KleynbergRLSchillerGJSecondary" exact="hemophagocytic lymphohistiocytosis" post="in adults: an update on diagnosis and therapyClin. Adv."/>
  <result pre="treatment for 2019-nCoV lung injuryLancet202039547347510.1016/S0140-6736(20)30317-232043983 208.WuCet al.Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
  <result pre="for 2019-nCoV lung injuryLancet202039547347510.1016/S0140-6736(20)30317-232043983 208.WuCet al.Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
  <result pre="lung injuryLancet202039547347510.1016/S0140-6736(20)30317-232043983 208.WuCet al.Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
  <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, ChinaJAMA Intern. Med.202018011110.1001/jamainternmed.2019.43467070509 209.RussellBet al.Associations"/>
  <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, ChinaJAMA Intern. Med.202018011110.1001/jamainternmed.2019.43467070509 209.RussellBet al.Associations between immune-suppressive"/>
  <result pre="corticosteroids on treatment failure among hospitalized patients with severe community-acquired" exact="pneumonia" post="and high inflammatory response: a randomized clinical trialJAMA201531367768610.1001/jama.2015.8825688779 213.LeeKYRhimJ-WKangJ-HEarly"/>
  <result pre="a randomized clinical trialJAMA201531367768610.1001/jama.2015.8825688779 213.LeeKYRhimJ-WKangJ-HEarly preemptive immunomodulators (corticosteroids) for severe" exact="pneumonia" post="patients infected with SARS-CoV-2Clin. Exp. Pediatr.20206311711810.3345/cep.2020.0029032272008 214.FadelRet al.Early short"/>
  <result pre="severe pneumonia patients infected with SARS-CoV-2Clin. Exp. Pediatr.20206311711810.3345/cep.2020.0029032272008 214.FadelRet al.Early" exact="short" post="course corticosteroids in hospitalized patients with COVID-19Clin. Infect. Dis.202010.1093/cid/ciaa60132945856"/>
  <result pre="Appraisal for COVID-19 Therapies (REACT) working groupAssociation between administration of" exact="systemic" post="corticosteroids and mortality among critically ill patients with COVID-19:"/>
  <result pre="J. Am. Soc. Nephrol.20181381582210.2215/CJN.1299111729475991 219.DusheikoGSide effects of alpha interferon in" exact="chronic hepatitis" post="CHepatology199726112S121S10.1002/hep.5102607209305675 220.AlattarRet al.Tocilizumab for the treatment of severe coronavirus"/>
  <result pre="Am. Soc. Nephrol.20181381582210.2215/CJN.1299111729475991 219.DusheikoGSide effects of alpha interferon in chronic" exact="hepatitis" post="CHepatology199726112S121S10.1002/hep.5102607209305675 220.AlattarRet al.Tocilizumab for the treatment of severe coronavirus"/>
  <result pre="hepatitis CHepatology199726112S121S10.1002/hep.5102607209305675 220.AlattarRet al.Tocilizumab for the treatment of severe coronavirus" exact="disease" post="2019J. Med. Virol.202010.1002/jmv.2596432965715 221.GuaraldiGet al.Tocilizumab in patients with severe"/>
  <result pre="Rheumatol.20202e59210.1016/S2665-9913(20)30313-132929415 224.DimopoulosGet al.Favorable anakinra responses in severe Covid-19 patients with" exact="secondary" post="hemophagocytic lymphohistiocytosisCell HostMicrobe202028117123.e1 225.AhnEet al.Role of PD-1 during effector"/>
  <result pre="al.Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during" exact="chronic" post="viral infectionProc. Natl Acad. Sci. USA2010107147331473810.1073/pnas.100973110720679213 227.KamphorstAOet al.Proliferation of"/>
  <result pre="of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic" exact="viral" post="infectionProc. Natl Acad. Sci. USA2010107147331473810.1073/pnas.100973110720679213 227.KamphorstAOet al.Proliferation of PD-1+"/>
  <result pre="Sci. USA2010107147331473810.1073/pnas.100973110720679213 227.KamphorstAOet al.Proliferation of PD-1+ CD8 T cells in" exact="peripheral" post="blood after PD-1-targeted therapy in lung cancer patientsProc. Natl"/>
  <result pre="CD8 T cells in peripheral blood after PD-1-targeted therapy in" exact="lung cancer" post="patientsProc. Natl Acad. Sci. USA20171144993499810.1073/pnas.170532711428446615 228.US National Library of"/>
  <result pre="T cells in peripheral blood after PD-1-targeted therapy in lung" exact="cancer" post="patientsProc. Natl Acad. Sci. USA20171144993499810.1073/pnas.170532711428446615 228.US National Library of"/>
  <result pre="2020). 236.ThachilJet al.ISTH interim guidance on recognition and management of" exact="coagulopathy" post="in COVID-19J. Thromb. Haemost.202081023102610.1111/jth.14810 237.US National Library of Medicine."/>
  <result pre="al.Identification of nafamostat as a potent inhibitor of Middle East" exact="respiratory" post="syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based"/>
  <result pre="of nafamostat as a potent inhibitor of Middle East respiratory" exact="syndrome" post="coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell"/>
  <result pre="248.KeshariRSet al.Complement C5 inhibition blocks the cytokine storm and consumptive" exact="coagulopathy" post="by decreasing lipopolysaccharide (LPS) release in E. coli sepsisBlood201512676576510.1182/blood.V126.23.765.765"/>
  <result pre="250.WoodruffTMNandakumarKSTedescoFInhibiting the C5â€&quot;C5a receptor axisMol. Immunol.2011481631164210.1016/j.molimm.2011.04.01421549429 251.WilliamsALet al.C5 inhibition prevents" exact="renal failure" post="in a mouse model of lethal C3 glomerulopathyKidney Int.2017911386139710.1016/j.kint.2016.11.01828139294"/>
  <result pre="model of lethal C3 glomerulopathyKidney Int.2017911386139710.1016/j.kint.2016.11.01828139294 252.NorisMRemuzziGTerminal complement effectors in" exact="atypical" post="hemolytic uremic syndrome: C5a, C5b-9, or a bit of"/>
  <result pre="or a bit of both?Kidney Int.201996131510.1016/j.kint.2019.02.03831229026 253.GattinoniLet al.COVID-19 pneumonia: different" exact="respiratory" post="treatments for different phenotypes?Intensive Care Med.2020461099110210.1007/s00134-020-06033-232291463 254.GattinoniLChiumelloDRossiSCOVID-19 pneumonia: ARDS"/>
  <result pre="rush to ventilate. Tildeshttps://www.reuters.com/article/us-health-coronavirus-ventilators-specia/special-report-as-virus-advances-doctors-rethink-rush-to-ventilate-idUSKCN2251PE (2020). 257.RobbaCet al.Distinct phenotypes require distinct" exact="respiratory" post="management strategies in severe COVID-19Respir. Physiol. Neurobiol.202027910345510.1016/j.resp.2020.10345532437877 258.CasadevallAPirofskiLThe convalescent"/>
  <result pre="ChinaJ. Med. Virol.202010.1002/jmv.2588232975825 262.ZengQLet al.Effect of convalescent plasma therapy on" exact="viral" post="shedding and survival in COVID-19 patientsJ. Infect. Dis.2020222384310.1093/infdis/jiaa22832348485 263.LiLet"/>
 </snippets>
</snippetsTree>
